Zhanel G G, Karlowsky J A, Saunders M H, Davidson R J, Hoban D J, Hancock R E, McLean I, Nicolle L E
Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Canada.
Antimicrob Agents Chemother. 1995 Feb;39(2):489-95. doi: 10.1128/AAC.39.2.489.
Laboratory-derived fluoroquinolone-resistant mutants were created by serially passaging wild-type Pseudomonas aeruginosa on fluoroquinolone-containing agar to obtain high-level fluoroquinolone resistance (e.g., ciprofloxacin MIC of 1,024 micrograms/ml). With increases of 4- to 32-fold in MICs of fluoroquinolones, these organisms demonstrated (relative to wild-type) normal morphology, resistance to fluoroquinolones only, no change in fluoroquinolone uptake, and no change in lipopolysaccharide profiles or outer membrane protein profiles. Complementation with wild-type Escherichia coli gyrA restored fluoroquinolone susceptibility, suggesting that these were gyrA mutants. After 4- to 32-fold increases in fluoroquinolone MICs (with continued passage on fluoroquinolone-containing agar) isolates demonstrated altered morphology, a multiple-antibiotic-resistant (Mar) phenotype (including cross-resistance to beta-lactams, chloramphenicol, and tetracycline), reduced fluoroquinolone uptake and altered outer membrane proteins (reductions in the 25- and 38-kDa bands as well as several bands in the 43- to 66-kDa region). Complementation with wild-type E. coli gyrA partially reduced the level of fluoroquinolone resistance by approximately 8- to 32-fold, suggesting that these mutants displayed both gyrA and non-gyrA mutations.
通过在含氟喹诺酮的琼脂上连续传代野生型铜绿假单胞菌来创建实验室衍生的氟喹诺酮耐药突变体,以获得高水平的氟喹诺酮耐药性(例如,环丙沙星的最低抑菌浓度为1024微克/毫升)。随着氟喹诺酮最低抑菌浓度增加4至32倍,这些菌株(相对于野生型)表现出正常形态,仅对氟喹诺酮耐药,氟喹诺酮摄取无变化,脂多糖谱和外膜蛋白谱也无变化。用野生型大肠杆菌gyrA进行互补可恢复氟喹诺酮敏感性,表明这些是gyrA突变体。在氟喹诺酮最低抑菌浓度增加4至32倍后(在含氟喹诺酮的琼脂上继续传代),分离株表现出形态改变、多重耐药(Mar)表型(包括对β-内酰胺类、氯霉素和四环素的交叉耐药)、氟喹诺酮摄取减少以及外膜蛋白改变(25 kDa和38 kDa条带以及43至66 kDa区域的几条条带减少)。用野生型大肠杆菌gyrA进行互补可使氟喹诺酮耐药水平部分降低约8至32倍,表明这些突变体同时存在gyrA和非gyrA突变。